COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) Fall Conference. A total of six studies (three clinical and three scientific studies) will be presented.
The clinical studies highlight the benefits of Osiris’s placenta-based products, Stravix®, Grafix® and GrafixPL®, for use in covering a variety of wound types. The scientific studies describe methods of cell viability evaluation in placental tissue and the structure and properties of tissues preserved using Osiris’s Prestige Lyotechnologysm, which retain all components of the native tissue including living cells but can be conveniently stored at ambient temperature. Key presentations and events are highlighted below.
Dr. Eric Johnson, MD, will present a lecture entitled “Scientific and Clinical Evidence for Grafix and GrafixPL: Cryopreserved and Lyopreserved Placental Membranes” on Friday, November 2, at 7:30am (Milano V-VI Ballroom, onsite registration available). Lecture objectives include:
- Information on how placental membranes benefit wound management
- An overview of how different tissue preservation methods impact the final composition of placental membrane products
- An introduction to Prestige Lyotechnology for ambient storage of placental membranes
- Clinical evidence for wound management with Grafix and GrafixPL
Dr. Charles E. Ananian, DPM, will present a poster summarizing results of a recently completed multicenter, prospective, randomized, single-blind trial comparing clinical outcomes and product cost between Grafix and Dermagraft®(1) in the treatment of chronic diabetic foot ulcers (DFUs)(2).
Dr. Alexander Reyzelman, DPM, FAPWCA, will present a poster describing the first prospective cases series evaluating clinical outcomes of GrafixPL, Osiris’s lyopreserved placental membrane, for the management of chronic wounds of various etiologies. This study demonstrates similar closure rates to previous studies utilizing Grafix, Osiris’s cryopreserved placental membrane, but with convenience of ambient storage.
Dr. Kathryn Davis, PhD, and Dr. Lawrence Lavery, DPM, MPH, will present a poster comparing amnion lyophilized by the Prestige Lyotechnology method (PL) to cryopreserved amnion. Data shows that the structure and cell viability of PL-lyophilized amnion is equivalent to those of cryopreserved viable amnion.
Scientific and clinical posters will be presented at the SAWC fall poster reception from 5:30 pm to 6:15 pm on Saturday, November 3 in the Forum Ballroom, Room 12.
The complete list of scientific and clinical abstracts includes:
- A Multicenter, Randomized, Single-Blind Trial Comparing the Efficacy of Viable Cryopreserved Placental Membrane to Human Fibroblast-Derived Dermal Substitute for the Treatment of Chronic Diabetic Foot Ulcers (Abstract CR-001)
- A Prospective, Single-Center, Open-Label Case Series Evaluating the Clinical Outcomes of Viable Lyopreserved Placental Membrane in the Treatment of Chronic Wounds (Abstract CS-063)
- Contralateral Limb Salvage in a Diabetic Amputee with Necrotizing Fasciitis: A Case Report Supporting the Use of Viable Cryopreserved Umbilical Tissue to Prevent Bilateral Amputation (Abstract CS-080)
- Structure and Cell Viability of Lyophilized Amniotic Membrane are Equivalent to Those of Cryopreserved Viable Amnion (Abstract LB-009)
- Structural Properties of Viable Lyophilized Placental Tissues (Abstract LB-020)
- Assessment of Human Amniotic Tissue Cell Viability (Abstract LB-028)
Osiris Therapeutics, Inc. will also be exhibiting at the Symposium on Advanced Wound Care Fall Meeting at booth 321. The event runs from November 2 through November 4, 2018 at Caesars Palace in Las Vegas, Nevada.
1-Dermagraft® is a registered trademark of Organogenesis, Inc. (Canton, MA)
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. We have achieved commercial success with products in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix®, BIO4® and Cartiform®. We continue to advance our research and development by focusing on innovation in regenerative medicine, including the development of bioengineered stem cell and tissue‑based products. Osiris®, Grafix®, GrafixPL®, GrafixPL PRIME™ Cartiform®, and Prestige Lyotechnologysm are our trademarks. BIO4® is a trademark of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation. More information can be found on the Company’s website, www.Osiris.com. (OSIR-G)
Statements herein relating to the future of Osiris Therapeutics, Inc. and the ongoing research and development of our products are forward-looking statements. Osiris Therapeutics, Inc. cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Osiris Therapeutics Inc. Annual Report on Form 10-K for the years ended December 31, 2017, 2016 and 2015 and Quarterly Report on Form 10-Q for the quarters ended March 31, 2018 and June 30, 2018, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of products and the likelihood of customer clinical adoption of any new products. Although well characterized in scientific literature and studies, preservation of tissue integrity, including cells, may not be indicative of clinical outcome. Accordingly, you should not unduly rely on these forward-looking statements. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
For additional information, please contact:
Osiris Therapeutics, Inc.